AnaptysBio, Inc. (FRA:AN6)

AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of EUR 994.54 million. The enterprise value is 1.08 billion.

Market Cap	994.54M
Enterprise Value	1.08B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	27.69M
Shares Outstanding	n/a
Shares Change (YoY)	+7.36%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	2.85%
Owned by Institutions (%)	70.65%
Float	14.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.89
PB Ratio	-39.67
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.95
EV / Sales	7.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.71

Financial Position

The company has a current ratio of 8.68

Current Ratio	8.68
Quick Ratio	8.52
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.38
Interest Coverage	-0.37

Financial Efficiency

Return on equity (ROE) is -308.02% and return on invested capital (ROIC) is -4.66%.

Return on Equity (ROE)	-308.02%
Return on Assets (ROA)	-4.23%
Return on Invested Capital (ROIC)	-4.66%
Return on Capital Employed (ROCE)	-9.10%
Revenue Per Employee	1.06M
Profits Per Employee	-530,369
Employee Count	136
Asset Turnover	0.40
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid 65,627 in taxes.

Income Tax	65,627
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +52.99% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+52.99%
50-Day Moving Average	28.80
200-Day Moving Average	20.96
Relative Strength Index (RSI)	68.42
Average Volume (20 Days)	80

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.74

Income Statement

In the last 12 months, AnaptysBio had revenue of EUR 144.44 million and -72.13 million in losses. Loss per share was -2.45.

Revenue	144.44M
Gross Profit	14.03M
Operating Income	-24.44M
Pretax Income	-72.06M
Net Income	-72.13M
EBITDA	-23.95M
EBIT	-24.44M
Loss Per Share	-2.45

Balance Sheet

The company has 212.19 million in cash and 295.28 million in debt, giving a net cash position of -83.09 million.

Cash & Cash Equivalents	212.19M
Total Debt	295.28M
Net Cash	-83.09M
Net Cash Per Share	n/a
Equity (Book Value)	-25.07M
Book Value Per Share	-0.91
Working Capital	249.34M

Cash Flow

In the last 12 months, operating cash flow was -123.56 million and capital expenditures -297,453, giving a free cash flow of -123.86 million.

Operating Cash Flow	-123.56M
Capital Expenditures	-297,453
Free Cash Flow	-123.86M
FCF Per Share	n/a

Margins

Gross margin is 9.72%, with operating and profit margins of -16.92% and -49.94%.

Gross Margin	9.72%
Operating Margin	-16.92%
Pretax Margin	-49.89%
Profit Margin	-49.94%
EBITDA Margin	-16.58%
EBIT Margin	-16.92%
FCF Margin	n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.36%
Shareholder Yield	-7.36%
Earnings Yield	-7.25%
FCF Yield	-12.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of -1.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.06
Piotroski F-Score	3